AMEVIVE® (Alefacept) Pregnancy Registry
Prospective reports will be collected from pregnant subjects, health care provider (HCP), or
Astellas Product Safety Management staff. Data from the pregnant subjects will be collected
at 4 to 5 months of pregnancy by telephone interviews with the Registry. The Registry will
also contact the subject at 2 months and 12 months after the estimated delivery date (EDD)
for post-natal & pediatric follow-up. The Registry will confirm the information collected
from the subject with the HCP by telephone interviews with the Registry, forms mailed/faxed
to the Registry, electronic forms/queries sent to the Registry, or a combination of these
methods. If a live birth is reported, the infant's HCP will be contacted for the Pediatric
Follow-Up at 2 months and 12 months of age. If a birth defect is reported, targeted
follow-up will be conducted.
Observational
Observational Model: Cohort, Time Perspective: Prospective
Evaluate pattern or increase in major birth defects in children of women w/ psoriasis who were exposed to AMEVIVE® at any time within the 8 wks prior to conception, or at any time during pregnancy, where outcome of the pregnancy is unknown prospectively
At month 4 to 5 of pregnancy; At 2 months and 12 months post estimated delivery date
No
Vice President Medical Affairs
Study Director
Astellas Pharma Global Development
United States: Institutional Review Board
0485-CL-0002
NCT00342862
March 2004
March 2012
Name | Location |
---|---|
INC Research | Wilmington, North Carolina 28405 |